Novo Nordisk Faces FDA Warning Over Ozempic Ad; Stock Rises 3.8%
Novo Nordisk received an FDA warning letter on Feb. 26 over false or misleading claims in its 'There's Only One Ozempic' TV ad, with regulators demanding a response within 15 days. Shares held an oversold RSI of 29.09 but still jumped 3.79% to $38.05, signaling trader rebound interest.
1. FDA Issues Warning Letter Over Ozempic Ad
On February 26, the FDA sent Novo Nordisk a warning letter alleging that its 'There’s Only One Ozempic' television advertisement made unapproved claims and misrepresented the drug’s indications and efficacy compared with other GLP-1 therapies. Regulators instructed the company to correct or cease distribution immediately and to submit a formal response within 15 days detailing its corrective actions.
2. Stock Rebounds From Oversold Territory
Novo Nordisk’s shares, which had fallen into oversold territory with a 14-day RSI of 29.09, rose 3.79% to $38.05 on the day the warning was disclosed. The intraday gain suggests traders viewed the pullback as a buying opportunity despite the regulatory notice, reflecting short-term mean-reversion trading dynamics.